CA2692392A1 - Anti- mcp-1 antibodies, compositions, methods and uses - Google Patents

Anti- mcp-1 antibodies, compositions, methods and uses Download PDF

Info

Publication number
CA2692392A1
CA2692392A1 CA002692392A CA2692392A CA2692392A1 CA 2692392 A1 CA2692392 A1 CA 2692392A1 CA 002692392 A CA002692392 A CA 002692392A CA 2692392 A CA2692392 A CA 2692392A CA 2692392 A1 CA2692392 A1 CA 2692392A1
Authority
CA
Canada
Prior art keywords
mcp
antibody
drug
human
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002692392A
Other languages
English (en)
French (fr)
Inventor
Anuk Das
Raymond Sweet
Ping Tsui
Deidra Bethea
Sheng-Jiun Wu
James Kang
Audrey Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692392A1 publication Critical patent/CA2692392A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002692392A 2007-06-29 2008-06-30 Anti- mcp-1 antibodies, compositions, methods and uses Abandoned CA2692392A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94698807P 2007-06-29 2007-06-29
US60/946,998 2007-06-29
PCT/US2008/068696 WO2009006359A2 (en) 2007-06-29 2008-06-30 Anti- mcp-1 antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
CA2692392A1 true CA2692392A1 (en) 2009-01-08

Family

ID=40158715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002692392A Abandoned CA2692392A1 (en) 2007-06-29 2008-06-30 Anti- mcp-1 antibodies, compositions, methods and uses

Country Status (8)

Country Link
US (1) US20100254992A1 (https=)
EP (1) EP2170387A4 (https=)
JP (1) JP2011517548A (https=)
CN (1) CN101827610A (https=)
AU (1) AU2008269954A1 (https=)
CA (1) CA2692392A1 (https=)
IL (1) IL202996A0 (https=)
WO (1) WO2009006359A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686008A1 (en) * 2011-03-15 2014-01-22 INSERM - Institut National de la Santé et de la Recherche Médicale Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence
TW201819398A (zh) * 2016-09-28 2018-06-01 美商寇峇有限公司 治療性肽
US11517608B2 (en) 2018-03-27 2022-12-06 Cohbar, Inc. Peptide-containing formulations
MX2022007479A (es) 2019-12-18 2022-06-29 Hoffmann La Roche Anticuerpos anti-ccl2 biespecificos.
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CA3221735A1 (en) * 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
CN118620076B (zh) * 2024-07-03 2024-12-17 武汉爱博泰克生物科技有限公司 用于检测鼠单核细胞趋化蛋白1的抗体和抗体对及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
JPH0967399A (ja) * 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
HU230769B1 (hu) * 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
CA2496419A1 (en) * 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2004050836A2 (en) * 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
US20100254992A1 (en) 2010-10-07
IL202996A0 (en) 2011-08-01
WO2009006359A8 (en) 2009-12-30
CN101827610A (zh) 2010-09-08
JP2011517548A (ja) 2011-06-16
EP2170387A4 (en) 2011-01-19
WO2009006359A2 (en) 2009-01-08
AU2008269954A1 (en) 2009-01-08
EP2170387A2 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
AU2010202813B2 (en) Anti- MCP-1 antibodies, compositions, methods and uses
US7371825B2 (en) Anti-MCP-1 antibodies, compositions, methods and uses
US8114964B2 (en) Anti-MCP-1 antibodies, compositions, methods and uses
EP2182943B1 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
CA3052095A1 (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
CA3052578A1 (en) Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
JP2008546374A5 (https=)
CA3133388A1 (en) Methods for producing anti-tnf antibody compositions
US20100254992A1 (en) Anti-mcp-1 antibodies, compositions, methods and uses
EP3938391A1 (en) Methods for producing anti-tnf antibody compositions
CA3133381A1 (en) Manufacturing methods for producing anti-tnf antibody compositions
WO2006125201A2 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
WO2007146857A2 (en) Anti- mcp-1 antibodies expressed in lemna, compositions, methods and uses
EP3914618A1 (en) Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130703